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Summary 
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a rare but 
increasingly recognized form of a cardiomyopathy, involving primarily the right 
ventricle. Mutations in four candidate genes coding for the ryanodine receptor, and 
three desmosomal proteins (plakoglobin, desmoplakin, plakophylin) are known to 
cause the disease in some patients. Typically, the right ventricular myocardium is 
replaced by fibrofatty infiltrates, leading to electrical instability and ventricular 
arrhythmias, reduced contractility and heart failure. The left ventricle may also be 
involved. Unfortunately, the disease is most often diagnosed post mortem, especially 
in young adults dying suddenly during exercise. Since the disease is inherited in up 
to 50% of cases, the screening of relatives is important. The advent of the ICD 
revolutionized the therapeutic approach in these patients. Nevertheless, the mortality 
of the disease remains to be 2 - 4% per year. The presence of left ventricular 
involvement and a history of congestive heart failure were identified as independent 
risk predictors for an adverse outcome. In this paper, we describe several clinical 
presentations of ARVC/D, discuss the algorithm for its diagnosis and provide a 
review of the literature. 
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Introduction 
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a rare 
disease entity, characterized by progressive fibrofatty replacement of the right 
ventricular myocardium (Table 1). The disease was first described by Frank and 
Fontaine in 1978 2 and it was recognized as a distinct cardiomyopathy eighteen years 
later 1. Clinically, patients with ARVC/D mostly present with ventricular arrhythmias, 
ranging from ventricular ectopic beats to sudden cardiac death as the first 
manifestation of the disease. Progressive right or biventricular involvement may lead 
to terminal heart failure, necessitating heart transplantation in the most severe cases. 
The prevalence of ARVC/D is higher in men than in women (1.6:1) and the incidence 
is highest between 5 and 40 years 2. The prevalence is estimated to range from 
6/10,000 in the general population to 44/10,000 in some areas in Northern Italy 3, 4 
and Germany 5. It is inherited in approximately 50%. ARVC/D is recognized as a 
cause of sudden, exercise-related deaths in athletes under 35 years of age 6, 7. It 
appears that sudden deaths in young athletes occur with a frequency of 1:100,000 to 
1:300,000 in the United States 7, with ARVC/D accounting for about 2-3% of these 
deaths 8. In Italy, however, this figure is tenfold higher 9. This difference may be due 
to a different genetic background, or due to the fact that there is a unique screening 
program for athletes engaging in competitive sports in Italy 10. ARVC/D also accounts 
for a significant number of non-exercise-related sudden deaths in the young, i.e. up 
to 20% both in Europe 6 and the United States 11. In addition, ARVC/D seems to be 
responsible for a certain number of early and unexpected postoperative deaths 12. If 
the disease is recognized in an early stage and if appropriate treatment is instituted, 
sudden cardiac death may be prevented in most cases. In this paper, we describe 
several different presentations of ARVC/D and provide a review of the literature on 
this rare but increasingly recognized disease. 
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Case Reports 
 
Patient 1 
A 20-year-old recruit of the Swiss army collapsed during a 12-minute-run. He was 
found pulseless, therefore basic cardiac life support was started immediately. An 
automated external defibrillator delivered an electrical shock based on the diagnosis 
of ventricular fibrillation. However, pulseless electrical activity followed. The patient 
was resuscitated by paramedics using repetitive administration of epinephrine and 
atropine. Airway protection was ensured by intubation and the patient was 
mechanically ventilated. As the patient was admitted to the hospital 25 minutes after 
the initial event, blood pressure could be measured again. At the hospital CT scans 
of the brain and the thorax revealed no abnormalities. A toxicology screening of the 
urine was negative. A 12-lead ECG was normal. Transthoracic echocardiography 
showed a dilated right ventricular outflow tract (Fig. 1) but was otherwise normal. 
However, two days after admission to the hospital, hypoxic cerebral edema 
developed and brain death was diagnosed. Post-mortem examination showed that 
the right ventricular musculature was partially replaced by fibrofatty tissue, a finding 
consistent with ARVC/D. His mother told later that her son had two episodes of 
syncope during adolescence, one shortly after running upstairs. A cardiological 
examination was suggested but not done. 
 
Patient 2 
A 24-year-old man lost consciousness 10 minutes after the start of a basketball 
game. Basic cardiac life support was performed by other players. After arrival of the 
emergency medical team an ECG showed asystole with occasional wide complexes. 
Advanced cardiac life support included intubation, mechanical ventilation and 
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transcutaneous pacing. Atropine and epinephrine were repetitively administered 
intravenously. Nevertheless, cardiopulmonary resuscitation was not successful and 
was stopped after one hour. The patient’s history was later taken from his parents. 
He had never suffered from a major disease. However, two uncles died from sudden 
cardiac death, and two other uncles had ARVC/D. Post-mortem examination showed 
that the right ventricle consisted partially of fibrofatty tissue (Fig. 2), a finding 
consistent with ARVC/D. Electrophysiological examination of the patient’s brother 
showed inducible sustained ventricular tachycardias, and an implantable 
cardioverter-defibrillator (ICD) was implanted. 
 
Patient 3 
A 51-year-old woman underwent laparoscopic abdominal surgery because of an 
intestinal obstruction due to a sigmoid volvulus. The initial postoperative course was 
uneventful. The postoperative ECG showed negative T-waves in the right precordial 
leads, which were thought to be due to a hypokalemia of 3.2 mmol/L. Potassium was 
supplemented and the patient was transferred to the ward. Four days after surgery, 
the patient was found unconscious and without a detectable pulse by the nurse on 
night shift. Cardiac resuscitation was started immediately, but careful examination 
showed that livores had already formed and cardiac life support was stopped. Post-
mortem examination revealed a dilated, hypertrophied right ventricle. Histology 
showed marked lipomatosis and a disturbed texture of the right ventricular 
myocardium, consistent with the diagnosis of ARVC/D. 
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Pathology 
The pathology material analyzed comes from autopsy studies and endomyocardial 
biopsies. The latter have to be sampled at the junction of the septum and the right 
ventricular free wall. Often, the biopsies are harvested from the septum, which is 
usually spared by the disease, and sampling errors result. The dilated right ventricle 
is covered by fatty tissue. There is a substantial (≥ 50%) fibrofatty infiltration of the 
subepicardial areas, with strands of normal or atrophied cardiomyocytes interspersed 
in-between (Fig. 2). The subendocardial cardiac muscle layer appears more or less 
normal. Fibrofatty infiltration of the His bundle and its two branches were found in 
68% of ARVC/D patients 13. However, high-degree AV-block is not a usual finding in 
ARVC/D patients. The thickness of the right myocardial free wall can be reduced. At 
a later stage, the left ventricle may also be involved in this process: In a study of 30 
hearts at autopsy, left ventricular involvement was found in 47% 14. 
 
Replacement of the RV myocardium by fibrofatty tissue is due to four basic 
mechanisms (Figure 3, 15): 
1. Apoptosis: Fragmented DNA and expression of protease CPP-32 are two major 
indicators of cellular apoptosis. Both were present in 75% of myocardial specimens 
from patients with ARVC/D 16. 
2. Dystrophy. Due to some metabolic or ultrastructural defect, there is progressive 
myocyte loss. The discovery of mutations in the ryanodine receptor or in 
desmosomal proteins indicate that this pathogenetic mechanism may be of major 
importance. 
3. Inflammation: Patchy inflammatory infiltrates are present in approximately two 
thirds of patients with ARVC/D 14. Viral myocarditis may be important 
pathogenetically, at least in non-familial forms of the disease. Bowles et al. found 
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enteroviral or adenoviral sequences in myocardial samples in most patients with 
ARVC/D 17. As the authors point out, it is not clear if ARVC/D patients are more 
prone to myocarditis or if myocarditis truly plays a pathogenetic role. In another study 
on sporadic cases of ARVC/D, myocarditis was diagnosed in 70% of 30 patients 
according to the Dallas criteria 18, indicating again that myocarditis involving the right 
ventricle is at least a major differential diagnosis of ARVC/D. On the other hand, 
Calabrese et al. were not able to find enteroviral genome using nested PCR 
technique 19. In their study of 20 patients, 45% had a family history for ARVC/D. The 
negative result may in part be explained by technical problems isolating RNA. 
4. Myocardial dysplasia, leading to adipogenesis and fibrogenesis. An example of 
maldeveloped right ventricular myocardium is Uhl’s anomaly, in which the right 
ventricular myocardium is absent at birth already and replaced by fibrous tissue 14. 
 
In some cases, the coronary arteries show increased thickness of the media, leading 
to luminal obstruction. This may explain the chest pain experienced by some 
patients. However, coronary artery obstruction does not play a major role in the 
pathogenesis of ARVC/D. The histological findings described above mirror the 
electrical reentrant phenomena and late potentials probably generated in the strands 
of cardiomyocytes within the fibrofatty tissue. However, environmental factors are 
important in the triggering of a life threatening arrhythmia 20. The histological analysis 
of the right ventricle showing massive fibrofatty replacement of the myocardium 
remains a hallmark of ARVC/D. Several animal models exist, including dogs, cats, 
minks, and mice 21,22,23 to study this rare disease entity. 
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Genetics 
In up to 50% of patients with ARVC/D a positive family history can be elicited 24. 
Usually, the disease is inherited as an autosomal dominant trait with incomplete and 
age-related penetrance and variable forms of clinical expression. Autosomal-
dominant forms of ARVC/D have been mapped to 9 different chromosomal loci by 
linkage analysis or direct sequencing of candidate genes (Table 2). In addition, three 
autosomal recessive forms of ARVC/D have been reported so far (Table 2). 
Although the first ARVC/D locus was identified in 1994, progress to identify genes 
and their mutations responsible for ARVC/D was rather slow, but four mutated 
proteins have been described so far. 
In ARVC/D 2, point mutations (single nucleotide polymorphisms or SNPs) were 
discovered in the human ryanodine receptor gene 2, and four RyR2 mutations 
(R176Q, L433P, N2386I, and T2504M) were identified to be transmitted from patient 
to patient along generations but were not detected in healthy relatives. The RyR2 
protein is a tetrameric protein essential for intracellular calcium homeostasis and 
excitation-contraction coupling. It links to the dihydropyridine receptor of the t-tubule, 
thus inducing release of calcium from the sarcoplasmatic reticulum to the cytosol 
upon membrane depolarization. The RyR2 missense mutations may disturb the 
calcium channel function and trigger apoptosis and cellular necrosis. Moreover, 
impaired intracellular calcium release may foster electrical instability 25.  
Two mutations involve the desmoplakin gene. One mutation (S299R) is transmitted 
as an autosomal-dominant trait (ARVC/D 8 26), and one as an autosomal-recessive 
trait inducing a distinct phenotype with woolly hair and a pemphigous-like skin 
disorder (27, G2375R). Desmoplakin (DSP), in conjunction with plakoglobin (JUP), 
anchors to desmosomal cadherins, forming an array of nontransmembrane proteins 
which join keratin intermediate filaments to the plasma membrane (Fig. 4). 
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Desmosomes serve as major cell-cell junctions, especially in epidermal cells and in 
cardiomyocytes 26.The S299R mutation disrupts a protein kinase C phosphorylation 
site at the amino-terminal domain 28. This phosphorylation site is important for the 
interaction with desmosomes at the plasma membrane side as well as for binding to 
plakoglobin. The G2375R mutation will impair desmoplakin binding to intermediate 
filaments 27. Both mutations may impair the right ventricular response to mechanical 
stress. Desmosomal dysfunction can lead to detachment of myocytes, with 
progressive apoptosis and fibrofatty replacement. 
The mutation of Naxos disease, which is inherited in an autosomal-recessive fashion, 
involves the plakoglobin gene (Table 2). The deletion of nucleotides 2157 and 2158 
causes a frameshift and premature termination of translation 29. Thus, the C-terminal 
domain of plakoglobin is shortened by 56 amino acid residues. 
Recently, several mutations in a gene encoding for plakophylin-2 protein(PKP2), 
which is also a constituent of desmosomes, have been described in ARVC/D patients 
30. Since mutations in desmosomal proteins such as PKP2, JUP, and DSP (Table 2) 
seem to be important in the pathogenesis of ARVC/D, the disease has been named 
“a disease of the desmosome” 30. It is of interest that mutations in the regulatory 
domain of the transforming growth factor-β3 gene were identified recently in patients 
with ARVC/D 1 31. TGF- β3 may play a role in desmosomal protein modulation. 
 
Clinical diagnosis 
As described in the case reports, several clinical manifestations are observed. 
Unfortunately, the first manifestation may well be a sudden cardiac death (7-23% 4). 
It may be heralded by palpitations, dizziness or even presyncope or syncope often 
related to physical exercise. These symptoms are due to ventricular arrhythmias and 
require further investigation. Very rarely, patients may complain of chest discomfort 
ARVC/D 
 - 10 - 
or anginal pain on exertion. The patients are usually young (33 ±14 years, range 13-
73 15), with a male predominance. In patients with less arrhythmogenic forms of the 
disease, symptoms and signs of heart failure may be the first presentation. 
Sometimes it will be difficult to make a differentiation from other cardiomyopathies. 
Physical examination may be normal in about 50% of patients. A wide splitting of S2 
due to delayed pulmonic closure secondary to RV dysfunction may be present 32. 
Tricuspid regurgitation murmur is sometimes observed, as well as an S3 gallop due 
to right ventricular failure. 
The major and minor criteria to diagnose ARVC/D are depicted in Table 1. Basically, 
global and/or regional dysfunction and structural alterations of the right ventricle 
should be documented by an imaging modality. ECG criteria include the presence of 
T-wave inversions in right precordial leads V2 and V3 with localized prolongation of 
the QRS complex (>110ms), Epsilon waves, and arrhythmias such as ventricular 
extrasystoles or ventricular tachycardias with LBBB morphology (Table 1). The 
propensity for arrhythmias may be quantitated by documentation of late potentials on 
signal-averaged ECG. An endomyocardial biopsy to show replacement of the right 
ventricular myocardium by fibrous or fatty tissue is only rarely performed because of 
possible sampling errors and the inherent complication rate of the procedure. A 
diagnosis of ARVC/D is made if either 2 major, 1 major and 2 minor, or 4 minor 
criteria are present, respectively (Table 1). 
In a retrospective analysis of 130 patients Hulot et al.33 showed that the natural 
history of the disease may be diverse. The overall mortality rate was 18.5% and the 
annual mortality rate was 2.3%. Mean age at death was 54 ± 19 years. The most 
important cause of death in this study cohort was progressive heart failure (59%) with 
sudden death being less frequent (29%). The documentation of ventricular 
tachycardias and clinical signs of right ventricular failure and/or left ventricular 
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dysfunction were risk factors for cardiovascular death. 
It remains a challenging task to predict which patients are at a high risk for sudden 
cardiac death. Established risk factors are (i) diffuse involvement and enlargement of 
the right ventricle, (ii) involvement of the left ventricle, (iii) impaired function of the 
right (and left) ventricle, and (iv) the presence of sustained ventricular tachycardias, 
induced during programmed electrical stimulation, when associated with an enlarged 
and dysfunctional right ventricle 4. 
At the University Hospital Zurich, Switzerland, sixty-one patients (mean age 44  14 
years; 44 males) were diagnosed with ARVC/D based on standardized diagnostic 
criteria 34. Among 41 patients who underwent electrophysiologic stimulation, 27 had 
an inducible sustained monomorphic ventricular tachycardia. Medical treatment 
included beta-blockers in 41 patients, sotalol in 19 patients, and amiodarone in 16 
patients. Twenty-four (39%) patients received an implantable cardioverter defibrillator 
(ICD) during follow-up. During a mean follow-up period of 55  47 months, ten 
patients with ARVC/D died. The annual rate of death in this patient cohort was 4%. 
The cause of death in eight patients was likely to be arrhythmic (sudden cardiac 
death; one of the patients had an ICD) and two patients died from advanced heart 
failure (one patient with ICD). Five patients underwent heart transplantation due to 
terminal heart failure. Risk factors significantly associated with adverse outcome 
(defined as sudden cardiac death, death from heart failure or need for heart 
transplantation) were a history of congestive heart failure (p<0.001), the presence of 
left ventricular involvement on echocardiography (p<0.001), left atrial dilatation 
(p<0.05), prolonged PR duration (p<0.01), prolonged QRS in V1 (p<0.05), and bundle 
branch block (p<0.05). In a multivariate analysis, a history of congestive heart failure 
and the presence of left ventricular involvement were identified as independent risk 
factors for an adverse outcome. 
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Evaluation of relatives 
Relatives of deceased patients often ask for a work-up to make sure that they are not 
carriers of the disease. Theoretically, the same criteria listed in Table 1 are used to 
screen relatives for the presence of the disease. However, Hamid et al. proposed 
that the original criteria 35 should be modified 36: The original criteria are highly 
specific but not sensitive enough to evaluate relatives who may have an early form of 
the disease. Therefore, they suggested that in first-degree relatives of patients with 
known ARVC/D any minor criterion listed in Table 1 will indicate familial involvement. 
In addition, they recommended that 200 instead of 1000 ventricular extrasystoles in a 
24 hour electrocardiogram constitute a criterion to diagnose the disease in this 
context. When these modified criteria are used to screen relatives, 39% of them will 
have signs of the disease, as opposed to 28% if the original criteria were used 36. A 
similar percentage (41%) was reported by Nava et al. 37. During a long-term follow-up 
(mean 8.5 years) of 37 Italian families encompassing 365 subjects, Nava et al. 
reported a favorable prognosis even for affected patients (mortality rate of 0.08 
patients/year) 37. Despite this fact, diligent medical care of these patients is of utmost 
importance and they should avoid strenuous physical activity. Screening of first-
degree relatives of patients with ARVC/D should include a medical history, a 
thorough physical examination, a standard 12-lead and a 24-hour ECG, a signal-
averaged ECG with 40mHz filter, a bicycle stress test, a transthoracic 
echocardiography, a cardiac MRI, and, if high-risk features such as palpitations, 
syncope, nonsustained or sustained ventricular tachycardias are present, an 
electrophysiological study. 
 
Screening of athletes 
ARVC/D is responsible for up to 20% of sudden deaths in young people, especially 
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for sudden deaths related to exercise38. Therefore, athletes wishing to engage in 
competitive activities should be screened 39. Questions to determine (i) if the 
individual has had effort-related chest pain, shortness of breath or syncope, (ii) if 
there is a family history of premature death, and (iii) if the patient has had elevated 
blood pressure or is known to have a heart murmur 40,41 should be asked. Two of the 
three screening questions are especially relevant regarding the diagnosis of 
ARVC/D. A thorough physical examination as well as a 12-lead ECG is 
recommended before engaging in competitive sports 39. However, distinctly abnormal 
ECGs can be found in healthy athletes performing endurance sports, e.g. cycling, 
cross-country skiing, rowing etc. 42. 27 of 145 “distinctly abnormal” ECGs of 1005 
Italian athletes showed marked repolarization abnormalities, including T-wave 
inversions in V1-V4 in 16 of the 27 patients. None of them had clinical features or 
imaging studies supporting a diagnosis of ARVC/D. Even if echocardiography should 
probably not be performed in every athlete because it is not considered cost-effective 
by some authorities 39, 8 it should be done in persons suspected to have structural 
heart disease. If ARVC/D is suspected clinically, further tests must be performed. A 
diagnosis of ARVC/D clearly precludes engagement in competitive sports 38,43,44, 
because physical exercise may trigger ventricular arrhythmias in patients with 
ARVC/D 45. Noncompetitive sports activities such as bowling, golf, and brisk walking 
are permitted 46. 
 
ARVC/D and perioperative deaths 
Tabib et al. reported a series of 50 patients who died postoperatively after low-risk 
surgery 12. In 18 of these patients (36%, mean age 30 ± 16 years) an ARVC/D was 
diagnosed. Four patients died during induction of anesthesia, nine during surgery 
and three within 2 hours postoperatively. In 19 out of 200 patients with ARVC/D who 
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died unexpectedly and suddenly, death occurred perioperatively, indicating that these 
patients may be difficult to resuscitate 13. The authors speculate that perioperative 
stress or drugs may trigger arrhythmias. Our case shows that death may occur even 
four days after the operation. Preoperative screening should include an ECG 47 and a 
chest X-ray even in younger patients. Special attention should be given to patients 
with a positive family history for sudden cardiac death. 
 
Electrocardiogaphy 
 
Standard 12-lead ECG 
The 12 leads ECG will be abnormal in 70% of the patients 32. As shown in Fig. 5, 
negative T waves are often present in leads V1-V3, sometimes extending to V5 or 
V6, especially in patients with left ventricular involvement. The duration of the QRS 
complex is often prolonged to ≥ 110ms. This prolongation of the QRS complex may 
be restricted to the right precordial leads V1-V3 5. In fact this differential prolongation 
of the QRS complex, defined as QRS duration in (V1+V2+V3) / (V4+V5+V6) ≥ 1.2, 
has a sensitivity of 98% and a specificity of 100% to diagnose ARVC/D 5. In addition, 
a new electrocardiographic marker for delayed right ventricular activation was 
recently described: The S-wave upstroke in leads V1 through V3, measured from the 
nadir of the S wave to the isoelectric baseline is prolonged to ≥ 55ms in patients with 
ARVC/D without right bundle branch block 48. This finding was the most prevalent 
ECG sign in patients with ARVC/D and also helped distinguish ARVC/D from benign 
forms of right ventricular outflow tract tachycardias. Moreover an epsilon-wave can 
be found in the right precordial leads, which corresponds to the asynchronous 
depolarization of the right ventricle. The epsilon-wave occurs after the QRS complex 
at the beginning of the ST-segment and consists of a small amplitude potential 
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(afterdepolarization). Using standard recording techniques a ε-wave will be found in a 
quarter of patients with ARVC/D. According to Fontaine, any potential in V1-V3 
exceeding the QRS duration in V6 by more than 25ms should be considered an 
epsilon-wave 15. Again in 25% of the patients elevations of the ST segment in right 
precordial leads are present, usually with upward convexity. In contrast, patients with 
a ST-segment elevation of coved or saddle-back type are likely to have the Brugada 
syndrome 49. 
Interestingly, duration and interlead variability of the QT interval and the QRS 
complex are greater in sudden death victims of ARVC/D compared to healthy 
controls and patients with milder forms of the disease 50. A QRS dispersion ≥ 40ms 
has a sensitivity and specificity of 90% and 77%, respectively, to predict sudden 
death. The increased QRS dispersion results mainly from the localized prolongation 
of the QRS complex in right precordial leads. Also, a QT dispersion > 65ms has a 
sensitivity of 85% and a specificity of 75% to predict sudden death 50. 
 
24-hour Holter ECG 
The 24-hour Holter ECG may reveal frequent multiple ventricular premature beats, 
i.e. >1000 per day, with a predominant LBBB morphology. In addition, nonsustained 
or sustained ventricular tachycardias with left bundle branch block (LBBB) 
morphology may occur. These two findings constitute two important minor criteria in 
the diagnosis of ARVC/D. Ventricular ectopic beats with a right bundle branch block 
(RBBB) morphology suggests left ventricular involvement. 
 
Exercise testing 
Careful analysis of arrhythmias during exercise is important, because ventricular 
tachycardias may be precipitated. The ventricular tachycardias with LBBB 
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morphology should be differentiated from the more benign right outflow tract 
ventricular tachycardias, which usually are found in patients without underlying 
cardiomyopathy. The right ventricular outflow tract ventricular tachycardias typically 
show an inferior axis orientation in the extremity leads (positive QRS vector in II, III, 
avF and negative QRS vector in aVL). In patients with ARVC/D this same axis is only 
observed, when the VT originate in the pulmonary infundibulum. More typically, there 
is a left axis deviation, because the majority of VT arises from the inferior wall or near 
the apex in patients with ARVC/D. The ventricular tachycardias with a superior axis 
are more frequent in patients with more extensive disease 51. For a reliable 
differentiation of right ventricular outflow tract tachycardias from arrhythmias in 
patients with ARVC/D an electrophysiological study may occasionally be 
necessary52, 53. 
 
Signal averaged ECG 
The value of signal averaged ECG in ARVC/D is controversial 15. It is used to detect 
delayed afterdepolarizations (“late potentials”). They mirror the presence of slowed 
electrical propagation in the myocardium, resulting in delayed ventricular activation. 
The presence of slowed ventricular activation provides a substrate for reentrant 
arrhythmias 54. Late potentials on signal-averaged ECG recordings are a minor 
criterion for the diagnosis of ARVC/D (Table 1). Late potentials on the signal-
averaged ECG are the counterpart of the epsilon waves recorded on the surface 
ECG. Consistent with other ECG abnormalities in ARVC, the abnormalities on signal-
averaged ECG are more prominent in the right precordial leads than they are in the 
left precordial leads. More extensive forms of the disease usually have more late 
potentials. Between 50% and 80% of patients with ARVC/D and sustained VT have 
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an abnormal signal-averaged ECG. Nava et al. examined 138 patients with ARVC/D 
and found that the signal-averaged ECG was abnormal in 57% of patients and 4% in 
healthy controls, and calculated a sensitivity of 57%, a specificity of 95%, and a 
positive predictive value of 92% 51. The signal-averaged ECG may be normal if the 
disease is localized to a small segment of the RV, but such patients are not immune 
to malignant arrhythmias. Abnormal signal-averaged ECG recordings are more 
common in patients with more severe myocardial fibrosis and reduced RV ejection 
fraction 55 and predict sustained VT among ARVC/D patients with prior nonsustained 
VT. A filtered QRS duration of > 110ms had the highest utility in identifying ARVC/D 
patients prone to inducible monomorphic VT’s on programmed electrical stimulation 
54. Signal-averaged ECGs should not be used in patients with QRS duration ≥ 120ms 
in the standard 12-lead ECG, as occurs in 20-30% of patients with ARVC/D. 
 
Echocardiography 
The right ventricle is more difficult to examine than the left. This is explained in part 
by its retrosternal location, and in part by its more complex geometry. Nevertheless, it 
must be examined in a systematic way 56, including the right ventricular inflow tract 
(RVIT), the right ventricular body (RVB), and the right ventricular outflow tract 
(RVOT). A protocol may be downloaded from the internet 
( HHUUhttp://anpat.unipd.it/ARVCUUHH). The goal of the examination is to measure the right 
ventricular dimensions, to quantify the function of the right ventricle, and to visualize 
the typical hallmarks of the disease (Fig. 6). Because the left ventricle may not be 
spared by the disease, it is equally important to examine the left ventricle. In fact, left 
ventricular wall motion abnormalities can be found in up to 25% of ARVC/D patients 
57. The three regions of the right ventricle, i.e. RVIT, RVB, and RVOT, can be 
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visualized as follows 58. All measurements are obtained at end-diastole: 
 
RVIT: From the standard parasternal long axis view the transducer is shifted to a 
point midway between the parasternal edge and cardiac apex. The transducer should 
then be tilted medially and downwards to obtain a view of the RVIT (normal mean 
value: 4.5cm, range 3.7-5.4), and the RVB (anterior and inferior wall, apex). It is 
important to exclude the RVOT from this view. The measurement of RVIT from this 
view is the most easily and consistently obtainable one. The RVIT can also be 
measured in the classical four chamber view or in a subcostal view.  
 
RVOT: The dimension of the RVOT can be measured by M-mode at enddiastole in 
the standard parasternal long axis view (normal values: 0.9-2.6cm, mean 1.7cm 59, 
59,60). The dimension of the RVOT should also be quantified in the parasternal short 
axis view at the aortic root level (normal mean value: 2.5±0.4 cm, range 1.8 - 3.4 61, 
Fig. 1). In a study of 29 patients with ARVC/D, dilatation of the RVOT was the most 
common and consistent finding. An RVOT diameter of >3.0cm measured in the 
parasternal long axis view had a sensitivity of 89% and a specificity of 86% for the 
diagnosis of ARVC/D 60. 
 
RVB: The dimensions of the RVB are best measured in the apical four chamber view. 
The diastolic length of the right ventricle from the apical endocardial border to the 
tricuspid annulus is 7.1±0.9cm, range 5.5-9.1). The longest distance between the 
septal and lateral free wall endocardium in a plane perpendicular to the right 
ventricular long axis is 3.0±0.5cm, range 2.1-4.2. Qualitatively, the degree of RV 
dilatation should be quantitated in relation to the left ventricle (mild: RV enlarged but 
area less than LV area; moderate: RV area equals LV area; severe: RV larger than 
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LV area). In an echocardiographic study of 15 patients with ARVC/D, cavity 
dimensions of RVOT, RVIT, and RVB were significantly larger compared with healthy 
controls 62. 
In ARVC/D patients, the right ventricular wall may be locally thickened or thinned. 
The normal RV wall thickness is defined to be 2.4±0.5mm 63. In normal subjects the 
thickness of the RV wall does not exceed 4mm 58. 
  
Regional wall motion abnormalities of the RV 
For the purpose of analyzing wall motion abnormalities, three walls of the right 
ventricle can be differentiated: the inferior or diaphragmatic wall, the ventricular 
septum and the free wall 64. The parasternal long axis view of the RVIT described 
above shows the inferoposterior wall directly underneath the tricuspid valve. This is 
the most important region to be examined, because it is frequently affected by 
ARVC/D. The lateral free wall of the right ventricle is best seen in the apical four 
chamber view. The right ventricle can also be subdivided in up to 12 segments, and 
each segment can be classified according to a score system: 0, not visualized; 1, 
normal; 2, mild hypokinesia; 3, severe hypokinesia; 4, akinesia; 5, dyskinesia; 6, 
isolated sacculations, bulges or outpouchings 57, 62. In patients with ARVC/D right 
ventricular wall motion abnormalities are the most frequent echocardiographic 
findings, being present in over 70% 57, 62. 
 
Right ventricular function 
Because of the complex right ventricular geometry, the function of the RV cannot be 
reliably quantitated by planimetry. Using two-dimensional echocardiography, Kaul et 
al. reported that the RV annular motion correlated with the RV ejection fraction 
measured by radionuclide ventriculography 65. More recently, RV function was 
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assessed by M-mode echocardiography measuring tricuspid annular movement. The 
M-mode cursor is directed to the lateral insertion of the tricuspid valve in the four-
chamber apical view. The normal value of the annular motion at the lateral tricuspid 
annular position is 2.5 ± 0.4 cm 62. In a group of 15 patients with ARVC/D, tricuspid 
annular motion in the lateral position was significantly decreased compared with 
healthy subjects (2.2 vs. 2.6 cm, p < 0.01 62). Moreover, tricuspid annular velocities 
can be assessed by pulsed tissue Doppler analysis.  
 
MRI 
This technique is very important in the diagnosis of ARVC/D because both cardiac 
structure and function can be evaluated 66. Using MRI, RV function, size, global or 
regional wall motion abnormalities, myocardial thinning and reduced systolic 
thickening can be quantitated. It is also possible to visualize the fibrofatty infiltration 
of the right ventricular myocardium. Technical requirements are a 1.5-T scanner with 
a cardiac phased-array surface coil for radiofrequency signal detection. If the patient 
has frequent extrasystoles, a betablocker should be administered prior to the 
investigation 66. For ECG-gated image acquisition, a double inversion recovery (blood 
suppression) fast spin-echo sequence should be used and the patient instructed to 
hold breath to minimize artifacts. Fat has the brightest signal intensity with the ECG-
gated spin-echo technique and the MRI is the best noninvasive technique to outline 
the infiltration of the RV myocardium with fat 32. Several protocols for an MRI 
examination of the heart in persons with suspected ARVC/D have been published 66, 
67, 68. In a retrospective analysis of 36 patients Keller et al. reported a sensitivity of 
89%, a specificity of 82%, a positive predictive value of 84%, and a negative 
predictive value of 88% to diagnose ARVC/D with MRI examination. The most 
important parameter in their study was (transmural) fatty tissue infiltration of the RV 
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67. This finding was confirmed in a prospective study. Quantitative analysis showed 
that RV enddiastolic diameter and outflow tract area were significantly higher, and 
RV ejection fraction lower in ARVC/D patients compared to controls 66. Using less 
dedicated software, the presence of fatty infiltration of the right ventricular 
myocardium may be less reliably detected 68. Moreover, even in normal individuals 
epicardial fat is usually present and tongues of epicardial fat may extend into the RV 
myocardium 68. ARVC/D patients, but not normal individuals, have fibrosis of the RV 
as well as fatty infiltrates, which both may be detected by MRI 69. The main role of 
cardiac MRI is probably its use as a screening tool for ARVC/D in relatives of patients 
with the disease and as a means of follow-up on ARVC/D patients 70. It is not the 
gold standard method to diagnose ARVC/D. 
The exact role of the MRI examination in the diagnosis of patients with idiopathic 
right ventricular outflow tract tachycardias with LBBB morphology remains to be 
determined. 15, 71, 68. 
 
Contrast ventriculography and endomyocardial biopsy 
Right ventricular ventriculography used to be the gold standard for the diagnosis of 
ARVC/D. Fontaine et al.15 suggested to obtain two orthogonal views of the RV (45° 
RAO, 45° LAO) and the use of digitized technique with 25 images/s to ensure optimal 
analysis and use of an angled 150° pigtail catheter. The main findings are 
schematically depicted in Fig. 6. In addition, the global and regional functions and the 
size of the RV must be quantitated. Slow evacuation of dye will be observed in areas 
rich in aneurysms and fissures and poor contractile function. 
Examination of the left ventricle will reveal abnormalities in 20-50% of ARVC/D 
patients. Most often, a mildly reduced LV systolic function will be found. It should be 
noted that a normal RV angiogram does not rule out ARVC/D. Hebert et al examined 
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85 patients with ARVC/D and reported that 68% had normal right ventricular function 
72. In their study, tricuspid annulus plane systolic excursion positively correlated with 
right ventricular function. If it was less than 12mm it identified patients with an RV 
ejection fraction < 35% with a sensitivity of 96% and a specificity of 78%. 
Endomyocardial biopsies to confirm fibrofatty infiltration should be done at the 
junction of the septum and the free wall. The sensitivity was reported to be 67% with 
a specificity of 92% 15. Often, the interventricular septum is not involved in the 
disease, and sampling errors may occur. Biopsy of the free wall of the RV carries a 
substantial risk of perforation. Therefore, endomyocardial biopsy cannot be 
recommended as a routine procedure. 
 
Electrophysiological testing with programmed electrical stimulation 
An intracardiac electrophysiological study with programmed ventricular stimulation 
should be reserved for symptomatic patients with sustained VT of VF, patients with 
syncopal episodes in whom non-invasive evaluation was negative, and asymptomatic 
patients with a family history of premature sudden death or non-sustained ventricular 
tachycardias and depressed right ventricular function (Fig. 7 73). The goals of the 
electrophysiologic study are: (i) to quantitate the potential to develop malignant 
arrhythmias, such as sustained VF and VF, (ii) to measure the hemodynamic 
consequences of these malignant arrhythmias, (iii) to evaluate the success of drug 
treatment on inducibility of arrhythmias and (iv) to establish the susceptibility of VT to 
be interrupted by antitachycardia stimulation before ICD implantation, and (v) to 
establish the basis for a radiofrequency ablation of a potential arrhythmic focus 74. 
The value of the electrophysiologic study for risk stratification in patients with 
ARVC/D is not known, however. Yet another key function of the invasive 
electrophysiological evaluation is to differentiate the usually benign right ventricular 
ARVC/D 
 - 23 - 
outflow tract tachycardia from ARVC/D. In patients with ARVC/D, the arrhythmias are 
usually inducible with critically timed extrastimuli, indicating a reentrant mechanism of 
the ventricular tachycardia. Moreover, in ARVC/D patients the ventricular 
tachycardias often show more than one morphology. In addition, fragmented 
potentials are more likely to be present in ARVC/D patients 52, 53. In contrast, right 
ventricular outflow tract tachycardias are generally not associated with a progressive 
condition, are seldom the cause of arrhythmic death, and are not known to be 
transmitted genetically. 
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Therapy 
 
Medical Therapy 
In the acute setting, treatment of a ventricular tachycardia should follow standard 
procedures. Synchronized electroconversion with 200 J using unipolar electrodes is 
performed in the presence of low blood pressure due to the tachycardia. Patients in 
cardiogenic shock and a very fast tachycardia will need unsynchronized defibrillation. 
Various drugs have been investigated to suppress the sometimes life-threatening 
arrhythmias of ARVC/D including betablockers, sotalol, and amiodarone 75. The most 
efficacious drug seems to be sotalol with an overall efficiency rate of 68% and 83% to 
treat both inducible and noninducible ventricular tachycardia in ARVC/D 75. However, 
due to the progressive nature of the disease, arrhythmias may recur despite initial 
success of the medication. Blomstrom-Lundqvist et al. reported a 20% mortality in 
their group of 15 patients followed-up for 9 years 76. These sobering numbers plus 
the fact, that non-inducibility of ventricular tachycardias during electrophysiologic 
studies does not rule out the occurrence of sudden death, led to the investigation of 
ICD therapy in ARVC/D patients. In patients suffering from symptoms and signs of 
heart failure, drug therapy including ACE-inhibitors/angiotensin receptor blockers, 
diuretics, and betablockers is adequate. This treatment may prevent progression of 
the disease, but further studies are necessary to address this issue. Patients with a 
dilated right ventricle and severely compromised function will need anticoagulant 
therapy as well. 
 
Radiofrequency catheter ablation 
Ventricular arrhythmias can be ablated with a high success rate in patients with 
RVOT tachycardia, but with limited success and a high recurrence rate in ARVC/D 
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patients 52, 74. This treatment may have more side effects (penetration of wires and 
leads) because of the diseased myocardium in ARVC/D. It should be tried in patients 
with very frequent ventricular tachycardias or in patients who cannot tolerate medical 
therapy. Late relapses occur because of the progressive nature of the disease 32. 
Radiofrequency ablation may be considered in ARVC/D patients who have frequent 
and drug-refractory VT after ICD implantation 73.  
 
ICD 
The experience with ICD therapy in patients with ARVC/D has been reported only 
recently and seven series have been published so far (Table 3). The implantation of 
an ICD device can effectively terminate life-threatening arrhythmias in patients with 
ARVC/D and should be considered standard therapy for these patients. However, 
several caveats need to be stated: Due to the progression of the disease, 
undersensing ultimately occurred in 13% of patients in the series by Wichter 77 
requiring surgical revision or implantation of additional leads. The risk of perforation 
of the thinned right ventricular wall may increase over time. Other lead problems 
included insulation failure, fracture, dislodgment, thrombosis, or infection. It is not 
surprising, therefore, that late complications occur in 21% of patients receiving ICD 
therapy (Table 3). In addition, inadequate ICD therapies are not uncommon. To 
diminish the frequency of both appropriate and inappropriate ICD shocks, there is a 
need for concomitant antiarrhythmic therapy including betablockers in 77% of 
patients (Table 3). 
The question which patients will benefit most from ICD therapy is not settled yet. 
Accepted indications for ICD therapy are (i) resuscitated sudden death and (ii) 
sustained ventricular tachycardias. Also, patients who have suffered a syncope with 
probable arrhythmogenic etiology should be considered for ICD implantation 
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(secondary prevention). It remains unclear, which patients with ARVC/D will require 
an ICD therapy for primary prevention of sudden cardiac death 78 and if the therapy 
should be offered for relatives with a high risk profile (inducibility of fast ventricular 
tachycardia during electrophysiologic study). According to Hodgkinson et al., patients 
with the presence of a high-risk DNA haplotype, and/or obligate carrier status by 
pedigree analysis, had a 28% reduction in mortality if an ICD was implanted for 
primary prophylaxis 78, indicating that genetic testing has a role in identifying patients 
at risk. Physicians are encouraged to register their patients in the European or the 
North American Registries (http://HHUUwww.arvd.com UUHH or http://HHUUwww.arvd.orgUUHH 79or 
HHUUhttp://anpat.unipd.it/ARVCUUHH 80). An informative website on ARVC/D can also be found 
at http://telethon.bio.unipd.it/ARVDnet. 
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Table 1 
Proposed clinical criteria for the diagnosis of ARVC/D 35, 24, 2 
Criteria Major Minor 
Global and/or regional 
dysfunction and structural 
alterations of the RV† 
Severe dilatation and 
reduction of RV ejection 
fraction with no or mild LV 
impairment 
Localized RV aneurysms 
Severe segmental dilatation 
of RV 
Mild global RV dilatation 
and/or ejection fraction 
reduction with normal LV 
function 
Mild segmental dilatation of 
RV 
Regional RV hypokinesia 
Tissue characterization of 
walls 
Fibrofatty replacement of 
myocardium on 
endomyocardial biopsy 
 
Repolarization abnormalities  Inverted T waves in right 
precordial leads V2 and V3 
(patient aged >12 years, 
RBBB absent) 
Depolarization/conduction 
abnormalities 
Epsilon waves or localized 
prolongation (110ms) of the 
QRS complex in precordial 
leads (V1 or V2 or V3) 
Late potentials (signal 
averaged ECG) 
Arrhythmias  LBBB type VT (sustained or 
non-sustained) (ECG, Holter, 
exercise testing) 
Frequent ventricular 
extrasystoles with LBBB 
morphology (≥ 1000 [>200] / 
24 h) (Holter) 
Family history Familial disease confirmed at 
surgery or autopsy 
Familial history of premature 
sudden death (age < 35 
years) due to suspected RV 
dysplasia 
Familial history (clinical 
diagnosis based on present 
criteria) 
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Table 1, continued 
 
RV=right ventricle, LV=left ventricle, VT=ventricular tachycardia 
†Detected by echocardiography, radionuclide scintigraphy, magnetic resonance 
imaging, or ventriculography 
For the diagnosis of ARVC/D 2 major, 1 major plus 2 minor, or 4 minor criteria are 
required, respectively. 
To screen relatives for familial ARVC/D the following modification has been 
suggested: ARVC/D in first-degree relative plus one of the criteria listed above in 
italics 36.  
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Table 2 
Chromosomal loci and candidate genes in ARVC/D 
ARVC/D 
Type, 
Reference 
OMIM™ 
number 
Chromosome 
Locus 
Gene Mode of 
inheritance 
Protein Phenotype Country of origin 
ARVC/D 1 
81,82 
107970 14q23-q24  autos.-dom.  Classical 
ARVC/D 
Italy 
ARVC/D 2 
83,3,84 
600996 1q42-q43 RyR2 autos.-dom. Human cardiac 
ryanodine 2 
receptor 
Effort-induced 
polymorphic VT’s, 
RV apical 
aneurysm 
Italy 
ARVC/D 3 85 602086 14q12-q22  autos.-dom.  Classical 
ARVC/D 
Italy, Slovenia, 
Belgium 
ARVC/D 
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Table 2, continued 
 
ARVC/D 
Type, 
Reference 
OMIM™ 
number 
Chromosome 
Locus 
Gene Mode of 
inheritance 
Protein Phenotype Country of origin 
ARVC/D 4 86 602087 2q32  autos.-dom.  Localized 
involvement of LV 
(in addition to RV)
Italy, U.S.A. 
ARVC/D 5 87 604400 3p23  autos.-dom.  Incomplete 
penetrance, late 
onset of disease 
Canada 
ARVC/D 6 
88,89 
604401 10p12-p14  autos.-dom.  High incidence of 
sudden death, 
early onset of 
disease 
U.S.A. (Anglo-
Saxon) 
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Table 2, continued 
 
ARVC/D 
Type, 
Reference 
OMIM™ 
number 
Chromosome 
Locus 
Gene Mode of 
inheritance 
Protein Phenotype Country of origin 
ARVC/D 7 90 -- 10q22  autos.-dom.  Skeletal muscle 
disease 
Sweden 
ARVC/D 8 26 607450 6p24 Desmoplakin 
(DSP) 
autos.-dom Desmoplakin No hair or skin 
alterations 
Italy 
ARVC/D 9 30 609040 12p11 Plakophyllin-
2 (PKP2) 
Autos.-dom. Plakophyllin-2 Incomplete 
penetrance. 
Classical 
ARVC/D 
Western European 
descent 
Naxos 
Disease 91,29 
601214 17q21 Plakoglobin 
(JUP) 
autos.-rec. Plakoglobin Palmoplantar 
keratoderma, 
woolly hair 
Greece 
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Table 2, continued 
 
ARVC/D 
Type, 
Reference 
OMIM™ 
number 
Chromosome 
Locus 
Gene Mode of 
inheritance 
Protein Phenotype Country of origin 
Carvajal 
Syndrome 92, 
27 
125647 6p24 Desmoplakin 
(DSP) 
autos.-rec. Desmoplakin Pemphigous-like 
skin disorder, 
woolly hair. No 
fibrofatty replace-
ment of 
myocardium. Left 
ventricular 
involvement. 
Israel (Muslim-Arab 
origin), Ecuador 
NN 93 115650 14q24-qter  autos.-rec.  Anterior polar 
cataract 
Argentina 
 
NN = No name given so far. OMIM™ = Online Mendelian Inheritance in Man ( HHUUhttp://www.ncbi.nlm.nih.gov/Omim/ UUHH) 
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Table 3 
ICD therapy in ARVC/D 
Author Years Number 
of 
patients 
and 
gender 
Mean 
age, 
years 
(range) 
F/U, 
months 
(mean 
± SD) 
Primary 
prevention 
(%) 
Patients on 
antiarrhythmic 
drugs at 
hospital 
discharge (%) 
Time to 
first ICD 
therapy, 
months 
(range) 
Appropriate 
ICD therapy 
during F/U 
(%) 
Inappropriate 
ICD therapy 
during F/U 
(%) 
Deaths/
HTx 
during 
F/U (%) 
Late 
complications 
(%) 
Wichter 77 1991-
2002 
60, 49 
m, 11 f 
43 (14-
70) 
80±43 7 54 4.1 (0.3-
41.4) 
60 23 13/3 45 
Roguin 94 1991-
2002 
42, 22 
m, 20 f 
36 (6-
69) 
42±26 40 97 9 (0.1-
66) 
78 24 2/2 14 
Corrado 95 1992-
2001 
132, 93 
m, 39 f 
40 (15-
72) 
39±27 22 83 22 (2-
96) 
48 16 3/2 14 
Hodgkinson 
78 
N/A 48, 30 
m, 18 f 
18 (15-
56) 
20 73 83 35 (0.5-
61) in 
males 
47 in males 10 0/10 in 
males, 
0/0 in 
females 
6 
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Author Years Number 
of 
patients 
and 
gender 
Mean 
age, 
years 
(range) 
F/U, 
months 
(mean±
SD) 
Primary 
prevention 
(%) 
Patients on 
antiarrhythmic 
drugs at 
hospital 
discharge (%) 
Time to 
first ICD 
therapy, 
months 
(range) 
Appropriate 
ICD therapy 
during F/U 
(%) 
Inappropriate 
ICD therapy 
during F/U 
(%) 
Deaths/
HTx 
during 
F/U (%) 
Late 
complications 
(%) 
Link 96 1992-
1995 
12, 7 m, 
5 f 
31 (15-
48) 
22 ± 13 0 58 N/A 67 33 8 25 
Tavernier 97 N/A 9, 8 m, 
1 f 
36 (11-
36) 
32 ± 24 0 89 N/A 78 44 0/11 N/A 
Breithardt 98 1990-
1993 
18  N/A 17 ± 11 0 N/A N/A 50 N/A N/A N/A 
 
m=male, f=female, N/A=not available, F/U=follow-up 
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Figure legends 
 
Fig. 1 
Echocardiographic parasternal short axis view. The right ventricular outflow tract 
(RVOT4) is dilated (at arrow 5cm [normal value: 1.8-3.4cm], Case 1). RA = right 
atrium, Ao = aortic valve, PA = pulmonary artery. 
 
Fig. 2 
The macroscopic aspect of the right ventricle shows replacement of the myocardium 
by fat and fibrous tissue. Strands of myocardium are visible within the fibrous-fatty 
tissue. 
 
Fig. 3 
Pathogenesis of ARVC/D. RV = right ventricular. See text for details. 
 
Fig. 4 
Molecular model of the desmosome (reprinted with permission from 99). The 
interaction between desmoglein and desmocollin, two desmosomal cadherin 
proteins, is crucial for the intercellular coherence. The desmoplakin, plakophilin, and 
plakoglobin proteins are important for the linkage of intermediate filaments to the cell 
membrane (its double layer is shown in black). The red dots show known mutations 
in ARVC/D patients. 
 
Fig. 5 
Typical ECG of a patient with a diffuse form of ARVC/D 48. Note the T-wave 
inversions (TWI) in leads V1-V5. An epsilon-wave is seen (notch or slurring of small 
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amplitude in the ST transition zone indicating prolongation of the depolarization 
phase, vertical arrow). The QRS complex duration in leads V1-V3 is slightly longer 
than in lead V6. Moreover, there is prolongation of the S-wave upstroke in V1 
through V3 of >55ms (reproduced with permission). 
 
Fig. 6 
Schematic drawing of a 45° right anterior oblique projection obtained during right 
ventricular (RV) cineventriculography. The diagnosis of ARVC/D is based on the 
presence of segmental morphologic abnormalities and wall motion abnormalities. 
The localized lesions are often present in the triangle of dysplasia, consisting of the 
pulmonary infundibulum, the anterior right ventricular wall including the apex, and the 
inferior wall including the subtricuspid area. The reduced contractility with slow 
evacuation of contrast material and the dilatation of the right ventricle, which is a 
frequent feature of ARVC/D, are not shown 15. The hyperreflective moderator band is 
an echocardiographic finding 60.  
 
Fig. 7 
Treatment strategy suggested for high-risk ARVC/D patients. See text for details. 
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Ab. 3 
Remodeling of RV myocardial structure and function
Apoptosis Adipo- and Fibrogenesis (dystrophy, dysplasia)
Inflammatory or
infectious process
Environmental factors /
Autonomic nervous system →
dispersion of refractoriness,
delayed afterdepolarizations
Concealed stage → Symptomatic arrhythmias → RV failure
Gene mutations (RyR2, JUP, DSP)
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Ab. 6 
Inflow Tract
Apex
Pulmonary infundibulum (ectasia)
Aneurysms
Diastolic bulging
of subtricuspid area
(mild) Tricuspid
regurgitation
Multiple outpouchings
Hypertrophic trabeculae with disarray
(hyperreflective moderator band)
Wall bulging
Outflow Tract
Dilatation
of RV
Myocardial thinning and
focal or diffuse fatty infiltration
(Pulmonary valve)
(Tricuspid valve)
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Ab. 7 
Electrophysiologic Study
Inducible VT
ICD
Heart transplantation
Non inducible VT
No cardiac arrest Cardiac arrest
Drug treatment
 
 
 
 
 
